Filtered By:
Therapy: Gene Therapy

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 490 results found since Jan 2013.

Attenuated Salmonella as a Delivery System for siRNA-Based Tumor Therapy
This technology comprises live, attenuated Salmonella strains as a delivery system for small interfering double-stranded RNA (siRNA)-based tumor therapy. The inventors' data provide the first convincing evidence that Salmonella can be used for delivering plasmid-based siRNAs into tumors growing in vivo. Claimed in the related patent application are methods of inhibiting the growth or reducing the volume of solid cancer tumors using the si-RNA constructs directed against genes that promote tumor survival and cancer cell growth. The Stat3-siRNAs carried by an attenuated S. typhimurium described in the application exhibit tum...
Source: NIH OTT Licensing Opportunities - January 9, 2009 Category: Research Authors: admin Source Type: research

Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice
Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice Gene Therapy advance online publication, April 16 2015. doi:10.1038/gt.2015.16 Authors: Y Pi, X Zhang, Z Shao, F Zhao, X Hu & Y Ao
Source: Gene Therapy - April 16, 2015 Category: Genetics & Stem Cells Authors: Y PiX ZhangZ ShaoF ZhaoX HuY Ao Source Type: research

Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro
Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro Gene Therapy advance online publication, June 18 2015. doi:10.1038/gt.2015.50 Authors: J C Evans, J McCarthy, C Torres-Fuentes, J F Cryan, J Ogier, R Darcy, R W Watson & C M O’Driscoll
Source: Gene Therapy - June 18, 2015 Category: Genetics & Stem Cells Authors: J C EvansJ McCarthyC Torres-FuentesJ F CryanJ OgierR DarcyR W WatsonC M O’Driscoll Source Type: research

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics
Publication date: Available online 8 August 2015 Source:Nano Today Author(s): João Conde, Alfredo Ambrosone, Yulán Hernandez, Furong Tian, Mark McCully, Catherine C. Berry, Pedro V. Baptista, Claudia Tortiglione, Jesus M. de la Fuente RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and signifi...
Source: Nano Today - August 9, 2015 Category: Nanotechnology Source Type: research

Modulating mammary tumor growth, metastasis and immunosuppression by siRNA-induced MIF reduction in tumor microenvironment
J A Kim
Source: Cancer Gene Therapy - September 25, 2015 Category: Cancer & Oncology Authors: M ZhangL YanJ A Kim Source Type: research

Nanomaterials as Non-viral siRNA Delivery Agents for Cancer Therapy.
Authors: Singh S Abstract Gene therapy has been recently shown as a promising tool for cancer treatment as nanotechnology-based safe and effective delivery methods are developed. Generally, genes are wrapped up in extremely tiny nanoparticles which could be taken up easily by cancer cells, not to their healthy neighboring cells. Several nanoparticle systems have been investigated primarily to address the problems involved in other methods of gene delivery and observed improved anticancer efficacy suggesting that nanomedicine provides novel opportunities to safely deliver genes, thus treat cancer. In this review, va...
Source: BioImpacts - December 13, 2015 Category: Research Tags: Bioimpacts Source Type: research

Precise and efficient siRNA design: a key point in competent gene silencing
-Toolabi
Source: Cancer Gene Therapy - March 18, 2016 Category: Cancer & Oncology Authors: E FakhrF ZareL Teimoori-Toolabi Source Type: research

siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases
siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases Gene Therapy advance online publication, July 7 2016. doi:10.1038/gt.2016.50 Authors: X Ma, P Zhou, S W Wong, M Warner, C Chaulagain & R L Comenzo
Source: Gene Therapy - July 6, 2016 Category: Genetics & Stem Cells Authors: X MaP ZhouS W WongM WarnerC ChaulagainR L Comenzo Source Type: research

Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy.
Abstract The lack of safe and effective gene delivery strategies remains a bottleneck for cancer gene therapy. Here, we describe the synthesis, characterization, and application of cell-penetrating peptide (CPP)-loaded nanobubbles (NBs), which are characterized by their safety, strong penetrating power and high gene loading capability for gene delivery. An epidermal growth factor receptor (EGFR)-targeted small interfering RNA (siEGFR) was transfected into triple negative breast cancer (TNBC) cells via prepared CPP-NBs synergized with ultrasound-targeted microbubble destruction (UTMD) technology. Fluorescence micro...
Source: Colloids and Surfaces - June 20, 2016 Category: Biotechnology Authors: Jing H, Cheng W, Li S, Wu B, Leng X, Xu S, Tian J Tags: Colloids Surf B Biointerfaces Source Type: research

The inhibition of epidermal growth factor receptor signaling by hexagonal selenium nanoparticles modified by SiRNA
A Jebali
Source: Cancer Gene Therapy - September 8, 2016 Category: Cancer & Oncology Authors: L Kamrani Moghaddam S Ramezani Paschepari M A Zaimy A Abdalaian A Jebali Source Type: research

Genetic pharmacology: progresses in siRNA delivery and therapeutic applications
Escriou
Source: Gene Therapy - February 15, 2017 Category: Genetics & Stem Cells Authors: D Scherman A Rousseau P Bigey V Escriou Source Type: research

532 siRNA based non-viral gene therapy for the treatment of epidermolysis bullosa simplex(EBS)
EBS is an inherited, skin fragility disorder predominantly caused by dominant-negative mutations in genes encoding for the cytoskeletal proteins, Keratin5 and Keratin14 within the basal cell layer. To date, EBS is incurable with only symptomatic therapies currently available. The downregulation of these mutant genes would provide an excellent curative therapy for treating EBS. siRNA therapeutics have been identified as an attractive therapy option for EBS given the highly accessible nature of skin tissue.
Source: Journal of Investigative Dermatology - April 12, 2017 Category: Dermatology Authors: J. O'Keeffe Ahern, D. Zhou, L. Cutlar, I. Lara-S áez, W. Wang Tags: Genetic Disease, Gene Regulation and Gene Therapy Source Type: research

478 Mutation-specific siRNA Knockdown of GJB2 − Potential gene therapy for Keratitis-ichthyosis-deafness Syndrome
Mutations in the GJB2 gene, which encodes connexin 26 (Cx26), cause keratitis-ichthyosis-deafness (KID) syndrome. 87% of patients carry a dominant mutation D50N, which is thought to cause a dominant negative effect on the normal allele product. Current treatment is limited to symptomatic care. We hypothesised that a mutation-specific siRNA to selectively suppress the D50N mutant allele may potentially reverse the disease phenotype. We first tested whether suppression of a single Cx26 allele can lead to haplo-insufficiency in human keratinocytes (KCs).
Source: Journal of Investigative Dermatology - April 12, 2017 Category: Dermatology Authors: M. Lee, V.A. Kinsler, S.L. Hart, W. Di Tags: Genetic Disease, Gene Regulation and Gene Therapy Source Type: research

Genetic pharmacology: progresses in siRNA delivery and therapeutic applications
Escriou
Source: Gene Therapy - February 16, 2017 Category: Genetics & Stem Cells Authors: D Scherman A Rousseau P Bigey V Escriou Source Type: research

A new combination therapy for asthma using dual-function dexamethasone-conjugated polyethylenimine and vitamin D binding protein siRNA
T Rhim
Source: Gene Therapy - September 21, 2017 Category: Genetics & Stem Cells Authors: M Choi J Gu M Lee T Rhim Source Type: research